Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for pneumonia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Tocilizumab in hospitalized patients with COVID-19 pneumonia CDEI - Tocilizumab in hospitalized patients with COVID-19 pneumonia — CDEI Open Menu Close Menu Open Menu Close Menu Sep 14 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information (medRxiv). Citation: Rosas, I. , Bräu, N., Waters, M., Go (...) , R. C., Hunter, B. D., Bhagani, S., ... Malhotra, A. (2020). Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv . DOI: Clinical trials registry link: Full PICO and Limitations in text: Population: 452 hospitalized patients (age 18 and older) with confirmed SARS-2-CoV infections and severe COVID-19 pneumonia. Intervention and Comparator Intervention: 301 patients were randomized to receive IV tocilizumab (8mg/kg infusion, max 800mg) along with standard care. (2nd infusion 8-24
Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: Results from a randomized controlled trial CDEI - Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia — CDEI Open Menu Close Menu Open Menu Close Menu Aug 24 Written By Citation: Miller, J. , Bruen, C., Schnaus, M., Zhang, J., Ali, S., Lind, A., Stoecker, Z., Stauderman, K., & Hebbar, S. (2020). Auxora versus standard of care for the treatment of severe or critical (...) COVID-19 pneumonia: Results from a randomized controlled trial. Critical Care , 24(1), 502. DOI: Full PICO and Limitations in text: Population: 30 adult patients diagnosed with confirmed SARS-CoV-2 infection, active symptoms and severe or critical COVID-19 pneumonia. Interventions and Comparator Intervention: 20 patients (17 severe, 3 critical) were randomized to receive 3 doses of once-daily Auxora (2 mg/kg at time 0 h, then 1.6 mg/kg (max 200 mg) at 24 and 48 h, administered as a 4-hour continuous
Complicated pneumonia in children. Complicated community-acquired pneumonia in a previously well child is a severe illness characterised by combinations of local complications (eg, parapneumonic effusion, empyema, necrotising pneumonia, and lung abscess) and systemic complications (eg, bacteraemia, metastatic infection, multiorgan failure, acute respiratory distress syndrome, disseminated intravascular coagulation, and, rarely, death). Complicated community-acquired pneumonia should (...) be suspected in any child with pneumonia not responding to appropriate antibiotic treatment within 48-72 h. Common causative organisms are Streptococcus pneumoniae and Staphylococcus aureus. Patients have initial imaging with chest radiography and ultrasound, which can also be used to assess the lung parenchyma, to identify pleural fluid; CT scanning is not usually indicated. Complicated pneumonia is treated with a prolonged course of intravenous antibiotics, and then oral antibiotics. The initial choice
Follow up of patients with a clinico-radiological diagnosis of COVID-19 pneumonia V1.2 11 May 2020 1 British Thoracic Society Guidance on Respiratory Follow Up of Patients with a Clinico-Radiological Diagnosis of COVID-19 Pneumonia Introduction This guidance outlines British Thoracic Society (BTS) recommended follow up of patients with a clinico-radiological diagnosis of COVID-19 pneumonia. The COVID-19 swab status of patients is not relevant to this guidance. The entry point to this guidance (...) is a clinical diagnosis of COVID-19 pneumonia with consistent radiological changes. This document may require updating as more information becomes available. This version was published on Monday 11 May 2020. Please check the BTS website for the most up to date version of this document. This guidance focuses on the radiological follow up of the pneumonic process and the subsequent diagnosis and management of respiratory complications of COVID-19 pneumonia. This guidance is intended to be pragmatic
Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children. Evidence regarding the appropriate duration of treatment with antibiotic agents in children with pneumonia in low-resource settings in Africa is lacking.We conducted a double-blind, randomized, controlled, noninferiority trial in Lilongwe, Malawi, to determine whether treatment with amoxicillin for 3 days is less effective than treatment for 5 days in children with chest-indrawing pneumonia (cough lasting <14 days (...) or difficulty breathing, along with visible indrawing of the chest wall with or without fast breathing for age). Children not infected with human immunodeficiency virus (HIV) who were 2 to 59 months of age and had chest-indrawing pneumonia were randomly assigned to receive amoxicillin twice daily for either 3 days or 5 days. Children were followed for 14 days. The primary outcome was treatment failure by day 6; noninferiority of the 3-day regimen to the 5-day regimen would be shown if the percentage
Randomized Trial of Amoxicillin for Pneumonia in Pakistan. The World Health Organization (WHO) recommends oral amoxicillin for patients who have pneumonia with tachypnea, yet trial data indicate that not using amoxicillin to treat this condition may be noninferior to using amoxicillin.We conducted a double-blind, randomized, placebo-controlled noninferiority trial involving children at primary health care centers in low-income communities in Karachi, Pakistan. Children who were 2 to 59 months (...) of age and who met WHO criteria for nonsevere pneumonia with tachypnea were randomly assigned to a 3-day course of a suspension of amoxicillin (the active control) of 50 mg per milliliter or matched volume of placebo (the test regimen), according to WHO weight bands (500 mg every 12 hours for a weight of 4 to <10 kg, 1000 mg every 12 hours for a weight of 10 to <14 kg, or 1500 mg every 12 hours for a weight of 14 to <20 kg). The primary outcome was treatment failure during the 3-day course
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen.Comparative observational study using data collected from routine care.Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March (...) 2020.181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care.Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group).The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress
Management of upper GI bleeding in patients with COVID-19 pneumonia Management of upper GI bleeding in patients with COVID-19 pneumonia Kimberly Cavaliere, 1 Calley Levine, 1 Praneet Wander, 1 Divyesh V Sejpal, 1 Arvind J Trindade 1 1) Division of Gastroenterology, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park, NY, USA ADDRESS CORRESPONDENCE: Dr. Arvind J. Trindade Director of Endoscopy Long Island Jewish Medical Center (...) to our hospital with COVID-19 –associated pneumonia (fever, shortness of breath requiring oxygen, positive COVID-19 polymerase chain reaction [PCR] test, and infiltrates showing on chest radiograph), and upper GI bleeding. The patient and clinical characteristics can be found in Table 1. The GI manifestations were hematemesis or melena. Guidelines advise that patients who present with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours of presentation 2 . Endoscopy can not only
Do Corticosteroids Benefit Patients With Influenza Pneumonia? Do Corticosteroids Benefit Patients With Influenza Pneumonia? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page To read this article in full, please review your options for gaining access at the bottom of the page. Article in Press Do Corticosteroids Benefit Patients With Influenza Pneumonia? x Michael Gottlieb , MD (EBEM Commentator) , x Thomas Seagraves , MD (EBEM (...) Commentator) , x Stephen R. Gore , MD (EBEM Commentator) Department of Emergency Medicine, Rush University Medical Center, Chicago, IL DOI: Publication History Published online: July 23, 2019 To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Among patients with influenza pneumonia, corticosteroids are associated with increased mortality, longer length of stay in the ICU, and higher rates of secondary infection, although there are no data from
Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis. In this systematic review and meta-analysis, we aimed to explore the association between cardiac injury and mortality, the need for intensive care unit (ICU) care, acute respiratory distress syndrome (ARDS), and severe coronavirus disease 2019 (COVID-19) in patients with COVID-19 pneumonia.We performed a comprehensive literature search from several databases. Definition of cardiac injury
Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Diabetes Mellitus (DM) is chronic conditions with devastating multi-systemic complication and may be associated with severe form of Coronavirus Disease 2019 (COVID-19). We conducted a systematic review and meta-analysis in order to investigate the association between DM and poor outcome in patients with COVID-19 pneumonia.Systematic (...) literature search was performed from several electronic databases on subjects that assess DM and outcome in COVID-19 pneumonia. The outcome of interest was composite poor outcome, including mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care unit (ICU) care, and disease progression.There were a total of 6452 patients from 30 studies. Meta-analysis showed that DM was associated with composite poor outcome (RR 2.38 [1.88, 3.03], p < 0.001; I2: 62%) and its
Enhanced oral hygiene interventions as a risk mitigation strategy for the prevention of non-ventilator-associated pneumonia: a systematic review and meta-analysis. Background Healthcare-acquired pneumonias are a significant risk for nursing home and hospital patients. While oral care interventions (OCIs) have been found to be effective in reducing the risk of ventilator-associated pneumonia (VAP), their utility in mitigating non-ventilator-associated pneumonias (NVAP) remains unknown. We
Vitamin C supplementation for prevention and treatment of pneumonia. According to the Global Burden of Disease Study 2015, lower respiratory tract infection is the leading cause of infectious disease death, and the fifth most common cause of death overall. Vitamin C has a role in modulating resistance to infectious agents, therefore vitamin C supplementation may be important in preventing and treating pneumonia.To assess the impact of vitamin C supplementation to prevent and treat pneumonia (...) of pneumonia in children and adults compared to control or placebo.We used standard methodological procedures expected by Cochrane.We included seven studies in the review and identified two ongoing studies. The seven included studies involved a total of 2774 participants; five studies were RCTs and two were quasi-RCTs. The included studies were conducted in high-income countries (UK, USA and Chile) and lower-middle-income countries (Bangladesh and Pakistan). Four studies were conducted in hospital